Ken Griffin Aldeyra Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 84,000 shares of ALDX stock, worth $324,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares

84,000

Previous 22,100 280.09%

Holding current value

$324,240

Previous $77,000 255.84%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $34,572 - $52,669	-12,481 Reduced 18.43%	55,248 $180,000
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $326,442 - $1.35 Million	-222,070 Reduced 76.63%	67,729 $237,000
Q3 2023 Nov 14, 2023	BUY	$6.11 - $8.16 $822,717 - $1.1 Million	134,651 Added 86.79%	289,799 $1.94 Million
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $235,305 - $393,499	-33,095 Reduced 17.58%	155,148 $1.3 Million
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $3.01 Million - $5.18 Million	-521,910 Reduced 73.49%	188,243 $1.87 Million

Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $4.85 Million - $6.76 Million	-953,975 Reduced 57.33%	710,153 $4.94 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $2.49 Million - $5.06 Million	-654,050 Reduced 28.21%	1,664,128 $8.89 Million
Q2 2022 Aug 15, 2022	SELL	$2.43 - $4.85 $392,099 - $782,586	-161,358 Reduced 6.51%	2,318,178 $9.25 Million
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $7.12 Million - $11.3 Million	2,190,919 Added 759.11%	2,479,536 $11 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $841,694 - $2.32 Million	240,484 Added 499.62%	288,617 $1.15 Million
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $159,244 - $226,833	20,056 Added 71.43%	48,133 $423,000
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $2.39 Million - $3.41 Million	-229,315 Reduced 89.09%	28,077 $318,000
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $6.98 Million - $15.4 Million	-1,068,295 Reduced 80.58%	257,392 $3.06 Million
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $1.87 Million - $2.41 Million	296,868 Added 28.86%	1,325,687 $9.09 Million
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $3.9 Million - $7.35 Million	975,512 Added 1829.99%	1,028,819 $7.62 Million
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $29,748 - $76,260	15,101 Added 39.53%	53,307 $223,000
Q1 2020 May 15, 2020	BUY	$1.62 - $6.4 $14,325 - $56,595	8,843 Added 30.12%	38,206 $95,000
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $57,460 - $96,941	12,148 Added 70.57%	29,363 $171,000
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $25,622 - $35,557	5,810 Added 50.94%	17,215 $90,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $129,018 - $193,527	-21,503 Reduced 65.34%	11,405 $68,000
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $142,514 - $196,606	19,960 Added 154.16%	32,908 $0
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $11,173 - $20,453	1,539 Added 13.49%	12,948 $107,000
Q2 2018 Aug 10, 2018	BUY	$6.95 - $9.18 $1,105 - $1,459	159 Added 1.41%	11,409 $0
Q1 2018 May 11, 2018	BUY	$6.55 - $8.9 $73,687 - $100,125	11,250 New	11,250 $84,000

Others Institutions Holding ALDX

# of Institutions

106

Shares Held

35.4M

Call Options Held

104K

Put Options Held

88.1K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $225M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account